The 1.5-day Gut Microbiome Conference has been conceived to immerse both clinicians and researchers in a comprehensive educational experience, designed to explore how the human microbiome and how altered microbial balance may contribute to chronic disorders such as diabetes/metabolic syndrome, gastrointestinal disorders (IBS, IBD, fatty liver disease), obesity, cancer, and even neurological conditions.

Goal Statement

To convene a group of researchers, physicians, and other healthcare professionals with a shared interest in the clinical importance and relevance of modulating the gut microbiome to revolutionize the management of infectious and chronic disease states in which human intestinal microbiota play a critical role. Through the extensive information presented on the pathophysiologic mechanisms of intestinal microbiota, novel detection modalities to assist accurate and timely diagnosis, and therapeutic approaches to manipulating and correcting dysbiosis, participants in the 1.5- day Gut Microbiome Conference will review the most current information emerging from a critical and burgeoning field of research and clinical development.


Target Audience

Gastroenterologists, internists, family practitioners, physician assistants, physicians-in-training and researchers with an interest in the pathophysiology, diagnosis, and clinical management of gastrointestinal and other common diseases and their relationship to the microbiome.

Statement of Need / Program Overview

Mounting evidence suggests an active and complex involvement of the intestinal microbiota in common chronic disorders such as diabetes/metabolic syndrome, gastrointestinal disorders (IBS, IBD, and fatty liver disease), obesity, cancer, and even neurological conditions. It is also increasingly clear that influencing the gut microbiome has the potential to revolutionize the management of not only infectious diseases, but a broad range of other conditions. Thus, clinicians would benefit from a better appreciation of how microbial-induced inflammation and immunological reactivity may assist in identifying the origins of diseases, classifying patient subgroups, and individualizing effective treatment strategies.

CME Educational Objectives

After completing this activity, participants should be better able to:

• Discuss evolving concepts regarding the role of the gut microbiome in gastrointestinal and liver health.

• Describe current research advances in understanding the composition and function of the gut microbiome.

• Discuss how modification of the gut microbiome can be used as a therapeutic strategy in gastrointestinal and liver health.


Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Cincinnati and the Gastrointestinal Health Foundation (GIHF). The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this live activity for a maximum of 11.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

All faculty and staff involved in the planning or presentation of continuing education activities provided by the University of Cincinnati are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.


All additional planning committee members, Gastrointestinal Health Foundation staff, and the University of Cincinnati staff  have no relationships to disclose.

Learner Assurance Statement

The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Off-Label Disclosure Statement

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Americans with Disabilities Act

The event staff will be glad to assist you with any special needs (i.e., physical, dietary). Please contact us prior to the event
at 1-973-520-1810.

Accredited by

Supported by an educational grant from Salix Pharmaceuticals.

Provided by

Provided by

  • Facebook Social Icon
  • Twitter Social Icon

© 2020 Gut Microbiome Conference. All rights reserved.